{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:50:20Z","timestamp":1767901820408,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":650,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.7861\/clinmed.22-4-s48","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T16:35:17Z","timestamp":1665506117000},"page":"48-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures"],"prefix":"10.1016","volume":"22","author":[{"given":"Jingwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.22-4-s48_bib1","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.7861\/clinmed.22-4-s48_bib2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"key":"10.7861\/clinmed.22-4-s48_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.0b013e318247ca8d","article-title":"Everolimus alters white matter diffusion in tuberous sclerosis complex","volume":"78","author":"Tillema","year":"2012","journal-title":"Neurology"},{"key":"10.7861\/clinmed.22-4-s48_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2018.10.005","article-title":"Longitudinal effects of everolimus on white matter diffusion in tuberous sclerosis complex","volume":"90","author":"Peters","year":"2019","journal-title":"Pediatric Neurology"},{"key":"10.7861\/clinmed.22-4-s48_bib5","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/epi.14085","article-title":"Everolimus dosing recommendations for tuberous sclerosis complex\u2013associated refractory seizures","volume":"59","author":"Franz","year":"2018","journal-title":"Epilepsia"},{"key":"10.7861\/clinmed.22-4-s48_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10928-018-9600-2","article-title":"Population pharmacokinetics\u2013pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex","volume":"45","author":"Combes","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10.7861\/clinmed.22-4-s48_bib7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"European Journal of Paediatric Neurology"},{"key":"10.7861\/clinmed.22-4-s48_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awizak","year":"2011","journal-title":"European Journal of Paediatric Neurology"},{"key":"10.7861\/clinmed.22-4-s48_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.07.008","article-title":"Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: A Long-Term, Prospective Trial","volume":"101","author":"Jozwiak","year":"2019","journal-title":"Pediatric Neurology"},{"key":"10.7861\/clinmed.22-4-s48_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3389\/fnmol.2018.00409","article-title":"Multiple critical periods for rapamycin treatment to correct structural defects in Tsc-1-suppressed brain","volume":"11","author":"Cox","year":"2018","journal-title":"Front Mol Neurosci"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824046980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824046980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.22-4-s48","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T22:33:20Z","timestamp":1740609200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824046980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1470211824046980"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.22-4-s48","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.22-4-s48","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2022. All rights reserved.","name":"copyright","label":"Copyright"}]}}